Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseRecruiting
NCT07203001Phase 2Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Still´s Disease
United States, Canada, France, Germany, Italy +3 more
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsRecruiting
NCT07006727Phase 1Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Small Cell Lung Carcinoma · Large Cell Neuroendocrine Carcinoma of the Lung · Neuroendocrine Prostate Cancer · Gastroenteropancreatic Neuroendocrine Carcinoma
United States, Canada, South Korea
Phase IIIb Study of Ribociclib + ET in Early Breast CancerRecruiting
NCT05827081Phase 3Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Early Breast Cancer
United States, Argentina, Australia, Brazil, Canada +11 more
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental VitiligoRecruiting
NCT07431177Phase 2Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Non-segmental Vitiligo
United States, Argentina, Australia, Canada, China +7 more
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Recruiting
NCT07357727Phase 3Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)
United States, Argentina, Australia, China, India +7 more
Modifying PEST for Psoriatic Arthritis ScreeningRecruiting
NCT06382051NAUpdated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Plaque Psoriasis · Psoriatic Arthritis
Canada
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaRecruiting
NCT07489573Phase 4Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
China
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive Not Recruiting
NCT03040973Phase 2Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Solid Tumors Which Are cMET-dependent
United States, Belgium, Canada, China, Denmark +6 more
A 52-week Study of Remibrutinib in IgE-mediated Food AllergyRecruiting
NCT07768371Phase 3Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
IgE-Mediated Food Allergy · Peanut Allergy · Cow Milk Allergy · Egg Allergy
United States
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaRecruiting
NCT06865651Phase 2Updated Sep 9, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
United States, France, Germany, Poland, Spain
The Mycophenolate Pregnancy RegistryRecruiting
NCT01733082N/AUpdated Sep 8, 2026
Sponsor: Genentech, Inc.
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
United States
Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD TrialNot Yet Recruiting
NCT07382414NAUpdated Sep 8, 2026
Sponsor: Tor Biering-Sørensen
Ischemic Heart Disease · Coronary Artery Disease · Hypercholesterolemia · Lipoprotein(a)
Denmark
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesRecruiting
NCT07102628Phase 3Updated Sep 8, 2026
Sponsor: Novartis Pharmaceuticals
Acute Coronary Syndrome
Argentina, Australia, Canada, China, France +9 more
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentRecruiting
NCT06955169Phase 2Updated Sep 8, 2026
Sponsor: RTOG Foundation, Inc.
Intracranial Meningioma
United States
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerRecruiting
NCT07604571Phase 1Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer
United States, Canada, Japan, Singapore, South Korea
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPAActive Not Recruiting
NCT06868290Phase 2Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
ANCA Associated Vasculitis (AAV)
United States, Brazil, Israel, Japan, Saudi Arabia +3 more
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsActive Not Recruiting
NCT06857955Phase 2Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Hypertension
United States, Japan, Singapore
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.Active Not Recruiting
NCT06247995Phase 1, Phase 2Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United States, Australia, Canada, China, France +6 more
Dabrafenib and/or Trametinib Rollover StudyRecruiting
NCT03340506Phase 4Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Melanoma · Non Small Cell Lung Cancer · Solid Tumor · Rare Cancers
United States, Argentina, Austria, China, Denmark +7 more
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)Active Not Recruiting
NCT06675864Phase 1, Phase 2Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Progressive Multiple Sclerosis
Australia, Canada, France, Germany, Italy +2 more
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsTerminated
NCT04315233Phase 1Updated Sep 4, 2026
Sponsor: University of Utah
Metastatic Breast Cancer · Recurrent Ovarian Carcinoma
United States
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's DiseaseActive Not Recruiting
NCT07048197Phase 1, Phase 2Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
France, Germany, Singapore, Spain
Study of MGY825 in Patients With Advanced Non-small Cell Lung CancerTerminated
NCT05275868Phase 1Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Non-small Cell Lung Cancer
United States, Germany, Japan, South Korea, Spain +1 more
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)Recruiting
NCT06997588Phase 2Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, Australia, Austria, Belgium, France +5 more
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Recruiting
NCT07517263Phase 3Updated Sep 4, 2026
Sponsor: Novartis Pharmaceuticals
Cardiovascular Disease and Lipoprotein(a)
United States, Argentina, Australia, Austria, Belgium +35 more

Previous page Next page